Browser does not support script.
Prior to randomising patients, centres must have sent copies of their SSA approval, R&D approval, Site Agreement and completed Centre Registration Form (and CTA or equivalent if a non-UK centre) to the AML Trials Office.
AML16 Patient Record Book AML16 Intensive Patient Record Book AML16 Non-Intensive Patient Record Book AML16 Randomisation Notepad Randomisation Notepad Intensive 1st Randomisation Randomisation Notepad Intensive 2nd Rand (Cons/Main) Randomisation Notepad Non-Intensive LD Ara-C v LD Clofarabine v Sapacitabine
Other Trial Documenation
AML16 Change of Trial Staff Form
AML16 Serious Adverse Event Form AML16 Trial Guides and Information NCI Toxicity Criteria AML16 PowerPoint Presentation (please contact AML Trials Office) AML16 Important Reference Numbers and Dates AML16 Lay Summary (please contact AML Trials Office) AML16 Sample Requirements AML16 Azacytadine - Gene methylation status assessment form AML16 Online Randomisation Guide for External Users AML16 Online Data Entry Guide for External Users Per Patient Payments There will not be any Per Patient Payments in the AML16 trial.
Print this page
Download as PDF
Send to a friend